Table 1.
Correlation between the clinicopathological features and expression of SLC25A21 in BCa.
| Characteristics | n | SLC25A21 protein expression | ||
|---|---|---|---|---|
| low (%) | high (%) | P value | ||
| Gender | ||||
| Male | 46 | 28 (60.1) | 18 (39.9) | 0.078 |
| Female | 10 | 9 (90) | 1 (10) | |
| Age(years) | ||||
| <69 | 26 | 18 (69.2) | 8 (30.8) | 0.642 |
| ≥69 | 30 | 19 (63.3) | 11 (36.7) | |
| Tumor diameter (cm) | ||||
| <5 | 34 | 22 (64.7) | 12 (35.3) | 0.788 |
| ≥5 | 22 | 15 (68.2) | 7 (31.8) | |
| Tumor grade | ||||
| Low | 18 | 9 (50.0) | 9 (50.0) | 0.080 |
| High | 38 | 28 (73.7) | 10 (26.3) | |
| Invasion | ||||
| No | 15 | 6 (40.0) | 9 (60.0) | 0.013 |
| Yes | 41 | 31 (75.6) | 10 (24.4) | |
| T stage | ||||
| Ta+Tis+T1 | 17 | 7 (41.2) | 10 (58.8) | 0.008 |
| T2 | 15 | 14 (93.3) | 1 (6.7) | |
| T3+T4 | 24 | 16 (66.7) | 8 (33.3) | |
| N stage | ||||
| N0 | 50 | 33 (66.0) | 17 (34.0) | 0.974 |
| N1~3 | 6 | 4 (66.7) | 2 (33.3) | |